|Bid||2.7000 x 1000|
|Ask||2.7300 x 1300|
|Day's Range||2.6200 - 2.8450|
|52 Week Range||2.3600 - 18.4200|
|Beta (5Y Monthly)||1.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 15, 2022 - Aug 19, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.17|
Subscribe to Yahoo Finance Plus to view Fair Value for CUE
It's not a secret that every investor will make bad investments, from time to time. But it would be foolish to simply...
BOSTON, June 13, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 15–16, 2022. During the fireside chat, Cue Biopharma will provide an overview highlighting its ongoing clinical trials and
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...